AKT1 and lung carcinoma: The targeting of the PI3K/Akt pathway might be an attractive therapeutic strategy to overcome the struggle of the clinical challenges of lung cancer tumor heterogeneity and acquired resistance, being important members of the flavonoids that are represented by apigenin and lutein [31].